BOCA RATON, Fla., Aug. 9, 2016 /PRNewswire/ -- IM HealthScience® (IMH) today announced that in response to growing feedback from doctors to make IBgard® more available for their patients, it is expanding retail access of IBgard®. More and more independent drug stores and grocery stores nationwide are now planning to make IBgard® available to patients. Leading national wholesalers, such as Amerisource Bergen and McKesson, are participating in this effort. IBgard® is a specially formulated and clinically studied, non-prescription medical food containing peppermint oil for the dietary management of Irritable Bowel Syndrome (IBS). The product is presently available in most CVS/pharmacy, Walgreens and Rite Aid stores nationwide.
Individuals with IBS have a significant burden affecting their daily quality of life and this points to the need for a more proactive approach in managing their condition. IBS is a condition that affects one in six Americans. It is a frustrating, under-diagnosed, and undertreated condition characterized by abdominal pain and other bowel symptoms. It can be severe – even unbearable – for some patients. IBgard® has been clinically proven to manage the symptoms of IBS, especially abdominal pain, in as early as 24 hours.
"Gastroenterologists tell us that IBgard® continues to deliver high levels of patient satisfaction," said Ellen Geisel, President of IM HealthScience®, innovators of IBgard®. "At this time of rising health care costs, IBgard® benefits from effectiveness, safety, retail access and affordability. We are pleased to be making IBgard® available to thousands of independent drug stores and grocery stores across the country through large and well-known national wholesalers. Independent drug stores and grocery stores will now be able to service their customers who seek more convenient retail access."
IBgard® capsules contain peppermint oil, including its principal component l-Menthol, in a unique delivery system. With its patented Site Specific Targeting (SST®) technology, pioneered by IM HealthScience®, IBgard® capsules release Ultramen®, an ultra-purified peppermint oil, in the small intestine. Peppermint oil can help toward normalizing the digestion of food and the absorption of nutrients, which have been compromised by IBS. Peppermint oil has also been shown to normalize intestinal transit time.
Over 10,000 health care practitioners, including 3,000 gastroenterologists, are estimated to have already used IBgard® for their patients. In a recent nationwide survey of gastroenterologists, IBgard® was the number one recommended peppermint oil for IBS. While IBgard® does not require a prescription, it must be used under medical supervision. Only doctors can diagnose IBS. The usual adult dose of IBgard® is 1-2 capsules as needed, up to three times a day, not to exceed 8 capsules per day.
IBgard® is available to patients in the digestive aisle at most CVS/pharmacy, Walgreens and Rite Aid stores nationwide and now increasingly in independent drug stores and grocery stores across the country.
About IM HealthScience®
IM HealthScience® (IMH) is the innovator of IBgard® for the dietary management of irritable bowel syndrome. It is a privately held company based in Boca Raton, Florida, that is also the innovator of FDgard® for the dietary management of functional dyspepsia. It was founded in 2010 by a team of highly experienced pharmaceutical research and development and management executives. The company is dedicated to developing products to address gastrointestinal issues where there is a high unmet need. The IM HealthScience® advantage comes from developing products based on its patented, targeted-delivery technologies called Site Specific Targeting (SST®). For more information, visit www.imhealthscience.com to learn about the company, or www.IBgard.com or www.FDgard.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/high-patient-satisfaction-and-demand-for-ibgard-results-in-expansion-of-availability-to-independent-drug-stores-and-grocery-stores-across-the-country-300310656.html
SOURCE IM HealthScience